Medication Safety During Dialysis: Clinical Considerations and Evidence-Based Approaches

Abstract

Ensuring medication safety during dialysis is a significant challenge due to altered pharmacokinetics, polypharmacy, and the high prevalence of comorbidities in patients with end-stage kidney disease (ESKD). This review synthesizes current evidence, clinical guidelines, and best practices to optimize medication use and minimize risks in the dialysis population. Emphasis is placed on mechanisms of drug clearance, identification of high-risk medications, and strategies for individualizing therapy to improve patient outcomes.

Introduction

The management of medications in patients undergoing dialysis is inherently complex. Dialysis patients often require multiple drugs to manage comorbid conditions such as hypertension, diabetes, and mineral-bone disorders. However, the altered pharmacokinetics resulting from renal failure and the dialysis process itself increase the risk of drug accumulation, toxicity, and adverse drug reactions (ADRs). Improving medication safety is critical for reducing hospitalizations and mortality in this vulnerable population. This article discusses the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of medication-related problems in dialysis, integrating recent advances and evidence-based guideline recommendations.

Epidemiology / Disease Burden

Globally, over 3 million individuals receive renal replacement therapy, with hemodialysis and peritoneal dialysis as the main modalities. Polypharmacy is prevalent, with studies reporting that dialysis patients are prescribed an average of 10–12 medications. Adverse drug events (ADEs) are common, contributing to approximately 15% of hospitalizations among dialysis patients. The burden of medication-related problems is amplified by the frequent use of drugs with narrow therapeutic indices, such as anticoagulants, antihypertensives, and antibiotics. Drug-drug interactions and inappropriate dosing further compound the risk of preventable harm, underscoring the need for systematic medication safety interventions.

Pathophysiology

Renal failure impairs the elimination of many medications, leading to accumulation of parent compounds or active metabolites. Dialysis, while facilitating removal of certain toxins and drugs, has variable efficacy depending on the molecular weight, protein binding, and volume of distribution of each agent. Hemodialysis primarily clears hydrophilic, low-molecular-weight, and non-protein-bound drugs, whereas peritoneal dialysis offers slower and less efficient drug removal. The interplay between residual renal function, dialysis modality, and pharmacokinetic alterations necessitates individualized medication dosing to prevent under- or overdosing.

Risk Factors

Several factors predispose dialysis patients to medication-related complications. These include advanced age, polypharmacy, cognitive impairment, hypoalbuminemia, and multiple comorbidities such as diabetes and cardiovascular disease. The use of nephrotoxic drugs, high pill burden, and frequent changes in medication regimens due to shifting clinical status also increase risk. Poor communication among multidisciplinary teams and incomplete medication reconciliation during care transitions further exacerbate safety concerns.

Clinical Features

Medication-related adverse events in dialysis patients may manifest as nonspecific symptoms such as confusion, gastrointestinal upset, or hypotension, complicating early recognition. More specific features include bleeding (with anticoagulant toxicity), arrhythmias (from electrolyte disturbances or QT-prolonging drugs), and heightened susceptibility to infections (with immunosuppressants or inappropriate antibiotic use). Subclinical toxicity may go unnoticed until significant morbidity occurs, highlighting the importance of routine monitoring and patient education.

Diagnosis

The diagnosis of medication-related problems in dialysis relies on a high index of suspicion, thorough medication review, and careful assessment of clinical status. Laboratory monitoring—such as drug levels for digoxin, vancomycin, or anticonvulsants—and assessment of renal and hepatic function are essential. Pharmacovigilance tools, such as the use of validated adverse drug reaction (ADR) causality scales and medication reconciliation checklists, support early detection and intervention.

Treatment & Management

Management strategies for medication safety in dialysis include dose adjustment based on renal function, scheduling drug administration to avoid removal during dialysis, and switching to agents with safer profiles when possible. Multidisciplinary medication reviews, involving nephrologists, pharmacists, and nurses, are key for optimizing regimens. Patient engagement through education about medication timing, potential interactions, and symptom monitoring is equally important. In cases of toxicity, supportive measures and, if indicated, enhanced drug clearance via dialysis are instituted.

Recent Advances / Emerging Therapies

Recent advances include the development of clinical decision support systems (CDSS) integrated with electronic health records to flag inappropriate prescribing and dosing errors in real time. Long-acting erythropoiesis-stimulating agents and phosphate binders with reduced pill burden are improving adherence and safety. Research into pharmacogenomics and personalized medicine holds promise for tailoring drug therapy to individual metabolic profiles, reducing ADRs and improving therapeutic efficacy. The use of telemedicine for remote medication monitoring and patient counseling has also shown potential, especially during the COVID-19 pandemic.

Guideline Recommendations

Current guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) and National Kidney Foundation (NKF) advocate for regular medication reconciliation at each dialysis visit, avoidance of nephrotoxic agents, and individualized dosing based on dialysis modality and residual renal function. High-risk drugs, such as opioids and antimicrobial agents, require special attention. Involvement of clinical pharmacists is strongly recommended to enhance medication safety. Guidelines emphasize ongoing education for healthcare professionals and patients alike, as well as the implementation of institutional protocols for monitoring and reporting medication errors.

Conclusion

Medication safety during dialysis demands a comprehensive, multidisciplinary approach that integrates pharmacokinetic principles, clinical vigilance, and evidence-based interventions. By adhering to guideline-driven practices, leveraging technological advances, and fostering patient engagement, healthcare teams can mitigate risks, improve outcomes, and enhance the quality of life for patients on dialysis. Continued research and innovation are essential to address the evolving challenges of medication management in this high-risk population.